Tesamorelin, bremelanotide and other peptide medicines: where the dose comes from

Approved peptide medicines carry an FDA label with a dosage section written for prescribers, so this page links each label instead of stating any dose.

Basics6 min read

Key takeaway

Six FDA-approved prescription medicines share an ingredient with peptides people often search. They are EGRIFTA WR (tesamorelin), Vyleesi (bremelanotide), Imcivree (setmelanotide), Forzinity (elamipretide), Scenesse (afamelanotide) and Increlex (mecasermin). Each has a narrow approved use and its own label. The only approved sermorelin products, sold as Geref, were discontinued in 2008. A licensed prescriber sets any dose from the label, which we link instead of quoting.

At a glance

Article typeBasics
TopicLaw & regulation
Studies cited0
Related productsResearch peptide catalog

People who search tesamorelin dosage, PT-141 dosage or sermorelin dosage usually want a number. This page does not give one, on purpose. Tesamorelin and bremelanotide (PT-141) are the active ingredients in FDA-approved prescription medicines, and a licensed prescriber sets each person's dose from the FDA label. Below are the approved products, a link to each official label, and what happened to sermorelin. Sources were checked on November 17, 2026.

Quick answer: The dose of an approved peptide medicine comes from its FDA label and a licensed prescriber, not from a web page. Tesamorelin is sold as EGRIFTA WR and bremelanotide (PT-141) as Vyleesi; both labels are linked in Table 1. No sermorelin product is FDA-approved today. Research-grade versions are laboratory reagents for laboratory research use only, not for human or veterinary use. They are never a source of dosing information.

Why doesn't this page list a dose?

Every currently approved product in Table 1 has the marketing status "Prescription" on Drugs@FDA. Each FDA label has a dosage and administration section written for prescribers. FDA rules say that section "must state the recommended dose" for the product. Where appropriate, it must also give doses for each approved use and patient group (21 CFR 201.57).

That detail matters because these medicines have narrow uses. A dose taken from one label, or from a forum, can be wrong for a different product, condition or person. The prescriber weighs the product, the approved use, your health history and your other medicines. Questions about a dose belong with that prescriber or your pharmacist.

Which peptide medicines are FDA-approved, and for what?

Table 1 lists approved peptide medicines related to peptides people often search, plus sermorelin. Approval dates come from Drugs@FDA and FDA approval letters. Approved uses come from each current label on DailyMed, the National Library of Medicine's label database. Labels change, so check the revision date on the label itself.

Table 1

FDA-approved peptide medicines people search dosage for (labels checked November 17, 2026)

Product (ingredient) Sponsor FDA approval Approved use on the current label Official label
EGRIFTA WR (tesamorelin) Theratechnologies Tesamorelin first approved November 2010; EGRIFTA WR formulation approved March 2025 Reduction of excess abdominal fat in adults with HIV and lipodystrophy. Not indicated for weight loss management DailyMed
Vyleesi (bremelanotide, also called PT-141) Cosette Pharmaceuticals (approved for AMAG Pharmaceuticals) June 2019 Premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) that meets the label's criteria. Not for postmenopausal women or men, and not to enhance sexual performance DailyMed
Imcivree (setmelanotide) Rhythm Pharmaceuticals November 2020; label expanded in 2022, 2024 and 2026 Excess body weight in certain rare obesities: Bardet-Biedl syndrome, genetically confirmed POMC, PCSK1 or LEPR deficiency, and acquired hypothalamic obesity, within the label's age limits. Not for general obesity DailyMed
Forzinity (elamipretide, also called SS-31) Stealth BioTherapeutics September 2025, accelerated approval To improve muscle strength in adults and children with Barth syndrome who meet the label's body-weight criterion. Continued approval may depend on a confirmatory trial DailyMed
Scenesse (afamelanotide) Clinuvel October 2019 To increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria (EPP) DailyMed
Increlex (mecasermin, a recombinant form of IGF-1) Ipsen at approval; current label from Eton Pharmaceuticals August 2005 Growth failure in children 2 and older with severe primary IGF-1 deficiency, or with growth hormone gene deletion and neutralizing antibodies to growth hormone. Not a substitute for growth hormone DailyMed
Geref (sermorelin) EMD Serono December 1990 (diagnostic product); September 1997 (treatment product) Discontinued in 2008. It was used for idiopathic growth hormone deficiency in children with growth failure, and as a diagnostic test No current label; see the 2013 FDA notice

Approval histories are on Drugs@FDA: EGRIFTA, Vyleesi, Imcivree, Forzinity, Scenesse, Increlex and Geref. DailyMed also still lists a label for the earlier EGRIFTA SV formulation.

Some details are easy to miss. The EGRIFTA WR label says it "is not indicated for weight loss management." Vyleesi is "not indicated to enhance sexual performance" (DailyMed). PubChem lists "melanotan I" as another name for afamelanotide (PubChem). Melanotan II is a different peptide, and Drugs@FDA lists no approved product containing it. For more on these compounds, see our pages on tesamorelin side effects, setmelanotide, afamelanotide and mecasermin.

What happened to sermorelin (Geref)?

Sermorelin was once an approved drug, sold by EMD Serono as Geref. A 2013 Federal Register notice tells the story (FDA, 2013). The diagnostic product was approved in December 1990, and the treatment product in September 1997. In 2008, EMD Serono told FDA it was discontinuing both. FDA withdrew approval of both applications effective June 18, 2009.

In 2013, after a citizen petition, FDA found that both Geref products "were not withdrawn for reasons of safety or effectiveness" (78 FR 14095). That finding allows FDA to approve generic versions if all other legal requirements are met. On November 17, 2026, Drugs@FDA listed no sermorelin product other than the discontinued Geref applications (Drugs@FDA). So there is no current FDA label to read. Products sold today under the sermorelin name are not Geref. Our page on sermorelin side effects covers what the Geref studies reported.

Why isn't research-grade material a substitute?

An approved medicine has been through FDA review of its safety, effectiveness, manufacturing and labeling, and it reaches you through a prescriber. Research-grade tesamorelin, PT-141 or SS-31 has none of that. It is a laboratory reagent, sold for laboratory research use only, not for human or veterinary use.

FDA has acted when such products were marketed for people. In an August 2026 warning letter, FDA found that research-labeled tesamorelin, PT-141 and SS-31 were drugs intended for human use. It reached that finding despite "not for human or veterinary use" statements (FDA, 2026). Our guide to FDA warning letters to peptide sellers explains the pattern. For peptides with no approval at all, see why research peptides have no dose.

Where should you go for a dose?

  • A licensed prescriber. A physician, nurse practitioner or physician assistant decides whether one of these medicines fits your condition, and at what dose.
  • The label. Use the DailyMed links in Table 1 to read the current label and patient information.
  • A licensed pharmacy. If you buy medicine online, FDA's BeSafeRx program explains how to check a pharmacy.
  • GLP-1 medicines. For semaglutide and tirzepatide, see semaglutide and tirzepatide dosage: why only a prescriber can set it.
  • Problems. Report side effects or medication errors to FDA through MedWatch or 1-888-INFO-FDA (1-888-463-6332), option 2.

Frequently asked questions about peptide medicine dosage

What is the tesamorelin dosage?

We do not state doses. Tesamorelin is sold as EGRIFTA WR, and a licensed prescriber sets the dose from its FDA label, linked in Table 1.

What is the PT-141 (Vyleesi) dosage?

Bremelanotide, also called PT-141, is sold as Vyleesi for a specific condition in premenopausal women. A prescriber sets the dose from the FDA label, which we link instead of quoting.

What was the sermorelin dosage?

The approved sermorelin products, sold as Geref, were discontinued in 2008, and there is no current FDA label. We do not restate historical doses; a clinician can discuss approved options.

Is tesamorelin approved for weight loss?

No. The EGRIFTA WR label approves it only to reduce excess abdominal fat in adults with HIV and lipodystrophy. It says the drug "is not indicated for weight loss management."

Is SS-31 (elamipretide) FDA-approved?

Yes, as Forzinity, under accelerated approval in September 2025. Its only approved use is to improve muscle strength in certain people with Barth syndrome.

Can research-grade tesamorelin or PT-141 be used instead?

No. Research-grade material is a laboratory reagent, not for human or veterinary use, and not a substitute for a prescription medicine.

What to know now

  • Prescription only: every product in Table 1 is listed by FDA as prescription.
  • Dose: set by a licensed prescriber from the FDA label; read the label on DailyMed.
  • Narrow uses: EGRIFTA WR is not for weight loss, and Vyleesi is not for enhancing sexual performance.
  • Sermorelin: Geref was discontinued in 2008; no approved sermorelin product is listed today.
  • Research grade: laboratory reagents, not for human or veterinary use, with no human dosing information.

What we're watching

Label revisions and new approved uses for these products, the confirmatory trial behind Forzinity's accelerated approval, and any FDA approval of a sermorelin product.

Also in the library

Sources: National Library of Medicine. DailyMed: EGRIFTA WR (tesamorelin), DailyMed: EGRIFTA WR (tesamorelin), Theratechnologies; National Library of Medicine. DailyMed: Vyleesi (bremelanotide), DailyMed: Vyleesi (bremelanotide), Cosette Pharmaceuticals; National Library of Medicine. DailyMed: Imcivree (setmelanotide), DailyMed: Imcivree (setmelanotide), Rhythm Pharmaceuticals; National Library of Medicine. DailyMed: Forzinity (elamipretide), DailyMed: Forzinity (elamipretide), Stealth BioTherapeutics; National Library of Medicine. DailyMed: Scenesse (afamelanotide), DailyMed: Scenesse (afamelanotide), Clinuvel; National Library of Medicine. DailyMed: Increlex (mecasermin), DailyMed: Increlex (mecasermin), Eton Pharmaceuticals; U.S. Food and Drug Administration 2025, Supplement approval letter, BLA 022505/S-020 (Egrifta WR); U.S. Food and Drug Administration 2019, Approval letter, NDA 210557 (Vyleesi); U.S. Food and Drug Administration 2025, Accelerated approval letter, NDA 215244 (Forzinity); U.S. Food and Drug Administration. Drugs@FDA: NDA 020443 (Geref) . https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020443, Drugs@FDA: NDA 020443 (Geref); U.S. Food and Drug Administration 2013; Code of Federal Regulations. 21 CFR 201.57: Specific requirements on content and format of labeling for human prescription drug and biological products . https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-B/section-201.57; National Center for Biotechnology Information. PubChem: afamelanotide (CID 16197727), PubChem: afamelanotide (CID 16197727), synonyms including melanotan I; National Center for Biotechnology Information. PubChem: bremelanotide (CID 9941379), PubChem: bremelanotide (CID 9941379), synonyms including PT-141; U.S. Food and Drug Administration 2026, Warning letter about research-labeled peptides, MARCS-CMS 735067; U.S. Food and Drug Administration. BeSafeRx: Your source for online pharmacy information . https://www.fda.gov/drugs/buying-using-medicine-safely/besaferx-your-source-online-pharmacy-information, BeSafeRx: Your source for online pharmacy information; U.S. Food and Drug Administration 2025, Reporting serious problems to FDA. All 17 citations

Back to the research library

References

  1. National Library of Medicine. DailyMed: EGRIFTA WR (tesamorelin), Theratechnologies (label revised March 2025). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75
  2. National Library of Medicine. DailyMed: Vyleesi (bremelanotide), Cosette Pharmaceuticals (label revised October 2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf
  3. National Library of Medicine. DailyMed: Imcivree (setmelanotide), Rhythm Pharmaceuticals. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70c3ccf7-4df0-4c75-ba07-fede9970c8d9
  4. National Library of Medicine. DailyMed: Forzinity (elamipretide), Stealth BioTherapeutics. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=146bf34c-76f2-48db-ac07-fb29cce2cd75
  5. National Library of Medicine. DailyMed: Scenesse (afamelanotide), Clinuvel. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94f53286-11dd-7fbb-e053-2a95a90a7c48
  6. National Library of Medicine. DailyMed: Increlex (mecasermin), Eton Pharmaceuticals. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5b2b0e1-c523-468d-9a0b-4ae4e4a8dbce
  7. U.S. Food and Drug Administration. (2025, March 25). Supplement approval letter, BLA 022505/S-020 (Egrifta WR). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/022505Orig1s020ltr.pdf
  8. U.S. Food and Drug Administration. (2019, June 21). Approval letter, NDA 210557 (Vyleesi). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/210557Orig1s000ltr.pdf
  9. U.S. Food and Drug Administration. (2025, September 19). Accelerated approval letter, NDA 215244 (Forzinity). https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/215244Orig1s000ltr.pdf
  10. U.S. Food and Drug Administration. Drugs@FDA: NDA 020443 (Geref). https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020443
  11. U.S. Food and Drug Administration. (2013, March 4). Determination that Geref (sermorelin acetate) injection products were not withdrawn from sale for reasons of safety or effectiveness (title shortened). Federal Register, 78 FR 14095. https://www.federalregister.gov/documents/2013/03/04/2013-04827
  12. Code of Federal Regulations. 21 CFR 201.57: Specific requirements on content and format of labeling for human prescription drug and biological products. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-B/section-201.57
  13. National Center for Biotechnology Information. PubChem: afamelanotide (CID 16197727), synonyms including melanotan I. https://pubchem.ncbi.nlm.nih.gov/compound/16197727
  14. National Center for Biotechnology Information. PubChem: bremelanotide (CID 9941379), synonyms including PT-141. https://pubchem.ncbi.nlm.nih.gov/compound/9941379
  15. U.S. Food and Drug Administration. (2026, August 24). Warning letter about research-labeled peptides, MARCS-CMS 735067. FDA warning letter on fda.gov
  16. U.S. Food and Drug Administration. BeSafeRx: Your source for online pharmacy information. https://www.fda.gov/drugs/buying-using-medicine-safely/besaferx-your-source-online-pharmacy-information
  17. U.S. Food and Drug Administration. (2025). Reporting serious problems to FDA. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program/reporting-serious-problems-fda